Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $19.78 USD
Change Today +0.33 / 1.70%
Volume 123.0K
VIVO On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

meridian bioscience inc (VIVO) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/6/15 - $20.62
52 Week Low
01/2/15 - $15.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

meridian bioscience inc (VIVO) Related Bloomberg News

View More Bloomberg News

meridian bioscience inc (VIVO) Related Businessweek News

No Related Businessweek News Found

meridian bioscience inc (VIVO) Details

Meridian Bioscience Inc., an integrated life science company, manufactures, develops, sells, and distributes diagnostic test kits. These are used primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. It also makes and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. In addition, it contract-manufactures proteins and other biologicals for biopharmaceutical and biotechnology companies researching new drugs and vaccines. Its products and technologies are marketed to hospitals, reference labs, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in about 60 countries. Meridian, founded in 1976, is based in Cincinnati.

meridian bioscience inc (VIVO) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $602.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $263.3K
Executive Vice President of Operations and In...
Total Annual Compensation: $408.9K
President of Meridian Bioscience Europe and M...
Total Annual Compensation: $356.7K
Executive Vice President and President of Mer...
Total Annual Compensation: $307.0K
Compensation as of Fiscal Year 2014.

meridian bioscience inc (VIVO) Key Developments

Meridian Receives FDA Clearance for New Molecular Whooping Cough Test Claims

Meridian Bioscience, Inc. announced it has received clearance from the U.S. Food and Drug Administration (FDA) for new claims for its illumigene Pertussis molecular amplification test. The upgraded test reduces the effect of inhibitors in biologic samples and significantly expands Meridian’s customer base by including specimens collected by ESwab (Copan Diagnostics, Inc.). ESwab is a multipurpose universal transport system that a significant portion of laboratories in the United States currently use to streamline workflows and eliminate costs associated with stocking multiple swab types. Often referred to as “whooping cough”, Bordetella pertussis can cause serious illness in infants, children and adults. Each year, there are approximately 16 million reported cases of pertussis worldwide and nearly 200,000 deaths. In the United States alone, almost 33,000 pertussis infections were reported in 2014, which represents a 15% increase compared to 2013. illumigene Pertussis, by amplifying the specific DNA target for the detection of Bordetella pertussis, provides a definitive result, thus helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner. By comparison, B. pertussis bacterial culture lacks sensitivity and is often impractical for patient management. Also, healthcare providers that send out to reference laboratories may have to wait more than a week for a test result delaying the necessary treatment for the patient. The illumigene Pertussis test procedure is remarkably simple, taking less than sixty minutes to report up to 10 results. It requires no expensive capital equipment, and no costly annual service contracts. The simplicity of this technology, along with its cost efficiency and small footprint, makes this innovative test ideal for enabling a more rapid diagnosis. Meridian is a fully integrated life science company that develops markets and distributes a broad range of innovative diagnostic tests, purified reagents and related products and offers biopharmaceutical enabling technologies in more than 60 countries worldwide. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines.

Meridian Bioscience, Inc. Declares Regular Cash Dividend for the Fourth Quarter Ended September 30, 2015, Payable November 27, 2015; Approves Indicated Regular Quarterly Cash Dividend Rate for Fiscal 2016; Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended September 30, 2015; Provides Earnings Guidance for the Fiscal Year Ending September 30, 2016

The Board of Directors of Meridian Bioscience, Inc. declared the regular quarterly cash dividend of $0.20 per share for the fourth quarter ended September 30, 2015. The dividend is of record November 16, 2015 and payable November 27, 2015. The Board of Directors has approved the indicated regular quarterly cash dividend rate of $0.20 per share for fiscal 2016, an annual indicated dividend rate of $0.80 per share, the same as the rate in fiscal 2015. The company reported unaudited earnings results for the fourth quarter and year ended September 30, 2015. For the quarter, the company reported net revenues of $47.068 million against $46.692 million a year ago. Operating income was $13.261 million against $11.968 million a year ago. Net earnings was $8.467 million against $8.182 million a year ago. Diluted earnings per share was $0.20 against $0.20 a year ago. Earnings before income taxes was $13.138 million against $12.174 million a year ago. For the year, the company reported net revenues of $194.830 million against $188.832 million a year ago. Operating income was $56.060 million against $52.392 million a year ago. Net earnings was $35.540 million against $34.743 million a year ago. Diluted earnings per share was $0.85 against $0.83 a year ago. Earnings before income taxes was $55.063 million against $52.108 million a year ago. The company expects tax rates to stabilize between 34-35% in fiscal 2016. For the fiscal year ending September 30, 2016, the company expects net revenues to be in the range of $195 million to $200 million and per share diluted earnings to be between $0.86 and $0.90.

Meridian Bioscience, Inc. to Report Q4, 2015 Results on Nov 05, 2015

Meridian Bioscience, Inc. announced that they will report Q4, 2015 results Pre-Market on Nov 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIVO:US $19.78 USD +0.33

VIVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ERBA Diagnostics Inc $1.24 USD 0.0001
GenMark Diagnostics Inc $7.65 USD +0.07
Luminex Corp $21.90 USD +0.01
Nanosphere Inc $1.13 USD -0.03
T2 Biosystems Inc $11.64 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation VIVO Industry Range
Price/Earnings 23.4x
Price/Sales 4.2x
Price/Book 5.0x
Price/Cash Flow 23.2x
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MERIDIAN BIOSCIENCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at